Comparative Pharmacology
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NOVOLOG FLEXPEN versus NOVOLOG MIX 50 50.
NOVOLOG FLEXPEN vs NOVOLOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin analog that lowers blood glucose by binding to insulin receptors, facilitating cellular uptake of glucose, and inhibiting hepatic glucose production.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Subcutaneous injection; 0.5 to 1.0 unit/kg/day divided into doses at mealtimes; dose individualization based on metabolic needs and blood glucose monitoring.
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
None Documented
None Documented
Terminal elimination half-life: 5-7 minutes (free insulin aspart in plasma); clinically, the prolonged action (up to 6 hours) reflects continued absorption from subcutaneous depot, not elimination half-life
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
Primarily renal (60-80% as unchanged drug via glomerular filtration and tubular reabsorption); biliary/fecal excretion minimal (<2%)
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Category C
Category C
Insulin Analog
Insulin Analog